MindWalk Holdings (HYFT) Deferred Taxes (2023 - 2026)

MindWalk Holdings (HYFT) posted quarterly Deferred Taxes of -$137876.6 for Q2 2026, down 1693.85% quarter-over-quarter from $8650.5 in Q4 2025.

Analysis

MindWalk Holdings (HYFT) Deferred Taxes (2023 - 2026) Analysis & Trends

MindWalk Holdings (HYFT) has reported Deferred Taxes for 4 consecutive years, with -$137876.6 the latest figure, recorded in Q2 2026.

In Q2 2026, Deferred Taxes changed N/A year-over-year to -$137876.6; the TTM figure through Apr 2026 stood at -$129226.1 (up 95.38% YoY), while the FY2026 annual figure was -$129122.6, up 95.43% from the prior year.
Deferred Taxes eased to -$137876.6 in Q2 2026 per HYFT's latest filing, from $8650.5 in the prior quarter.
Across five years, Deferred Taxes topped out at $8650.5 in Q4 2025 and bottomed at -$2.1 million in Q1 2025.
Historically, Deferred Taxes has averaged -$419542.3 across 4 years, with a median of -$191279.8 in 2023.
On a YoY basis, Deferred Taxes climbed as much as 103.58% in 2025 and fell as far as 255.46% in 2025.
MindWalk Holdings' Deferred Taxes stood at -$147498.8 in 2023, then sank by 63.84% to -$241655.3 in 2024, then surged by 103.58% to $8650.5 in 2025, then sank by 1693.85% to -$137876.6 in 2026.
Business Quant data shows HYFT's Deferred Taxes at -$137876.6 in Q2 2026, $8650.5 in Q4 2025, and -$2.1 million in Q1 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	138.78 Bn	130.92 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	85.50 Bn	77.51 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn	-
4	Moderna	58.06 Bn	52.92 Bn	52.00 Mn	-
5	Revolution Medicines	44.04 Bn	44.04 Bn	-	-
6	BeOne Medicines	40.04 Bn	34.94 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn	2.66 Mn
8	Royalty Pharma	28.41 Bn	27.57 Bn	-	-
9	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-
10	MindWalk Holdings	61.69 Mn	53.41 Mn	1.82 Mn	-137,876.64

Historic Data

Download Data